Parallel Advisors, LLC Day One Biopharmaceuticals, Inc. Transaction History
Parallel Advisors, LLC
- $4.87 Billion
- Q2 2025
A detailed history of Parallel Advisors, LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 142 shares of DAWN stock, worth $994. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142
Previous 4
3450.0%
Holding current value
$994
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding DAWN
# of Institutions
196Shares Held
76.7MCall Options Held
138KPut Options Held
208K-
Atlas Venture Life Science Advisors, LLC6.43MShares$45 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$41.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$40.3 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$31.7 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$28.4 Million0.14% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $514M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...